✦ LIBER ✦

Phase II study of carboplatin (CBDCA) in refractory multiple myeloma

✍ Scribed by Bart Barlogie; John Crowley; Sydney E. Salmon; John Bonnet; James K. Weick; Kathy Hayden

Publisher: Springer US
Year: 1994
Tongue: English
Weight: 233 KB
Volume: 12
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873237

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of bisantrene in ref

Phase II evaluation of bisantrene in refractory multiple myeloma

✍ Brian G. M. Durie; John Crowley; Charles A. Coltman; Robert A. Chapman; Stanley 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 205 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Pilot study of 5-azacytidine (5-AZA) and

Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia

✍ Kritz, Alan D.; Raptis, George; Menendez-Botet, Celia; Maslak, Peter; Jakubowski 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB 👁 2 views

5-azacytidine (5-AZA) and carboplatin (CBDCA) are two agents which have demonstrated antileukemic activity In a number of phase 1-11 trials. Their mechanisms of action and pharmacology related to cell resistance suggested sultabiiity for combination therapy. The aim of this pilot study was to evalua

Carboplatin (CBDCA) and radiotherapy for

Carboplatin (CBDCA) and radiotherapy for stage IV carcinoma of the head and neck: A phase I–II study

✍ Maria C. Jacobs; Mario Eisenberger; Min Chu Oh; Victoria Sinibaldi; William Gray 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 431 KB

Combined thalidomide and cyclophosphamid

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study

✍ Sjoerd Hovenga; Simon M. G. J. Daenen; Joost T. M. de Wolf; Gustaaf W. van Imhof 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 118 KB

Phase II trial of amsacrine in patients

Phase II trial of amsacrine in patients with multiple myeloma

✍ Greipp, Philip R. ;Coleman, Morton ;Anderson, Keaven ;McIntyre, O. Ross 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more